NO20081727L - Behandling av autoimmune sykdommer - Google Patents

Behandling av autoimmune sykdommer

Info

Publication number
NO20081727L
NO20081727L NO20081727A NO20081727A NO20081727L NO 20081727 L NO20081727 L NO 20081727L NO 20081727 A NO20081727 A NO 20081727A NO 20081727 A NO20081727 A NO 20081727A NO 20081727 L NO20081727 L NO 20081727L
Authority
NO
Norway
Prior art keywords
autoimmune diseases
treatment
neuritis
uveitis
methods
Prior art date
Application number
NO20081727A
Other languages
English (en)
Norwegian (no)
Inventor
Rainer Albert
Nigel Graham Cooke
Sven Weiler
Barbara Nuesslein-Hildesheim
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20081727L publication Critical patent/NO20081727L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20081727A 2005-09-09 2008-04-07 Behandling av autoimmune sykdommer NO20081727L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71599005P 2005-09-09 2005-09-09
PCT/EP2006/066150 WO2007028821A2 (en) 2005-09-09 2006-09-07 Treatment of autoimmune diseases

Publications (1)

Publication Number Publication Date
NO20081727L true NO20081727L (no) 2008-06-06

Family

ID=37056992

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081727A NO20081727L (no) 2005-09-09 2008-04-07 Behandling av autoimmune sykdommer

Country Status (29)

Country Link
US (1) US20080200438A1 (de)
EP (2) EP1926483B1 (de)
JP (4) JP5244598B2 (de)
KR (3) KR101476591B1 (de)
CN (1) CN101257899B (de)
AT (1) ATE489948T1 (de)
AU (2) AU2006289100B2 (de)
BR (1) BRPI0615906A2 (de)
CA (2) CA2620554C (de)
CY (1) CY1111285T1 (de)
DE (1) DE602006018629D1 (de)
DK (2) DK2295049T3 (de)
ES (2) ES2357426T3 (de)
HK (1) HK1149906A1 (de)
IL (2) IL189665A (de)
JO (1) JO2655B1 (de)
MA (1) MA29787B1 (de)
MX (1) MX2008003170A (de)
NO (1) NO20081727L (de)
NZ (2) NZ566137A (de)
PL (2) PL2295049T3 (de)
PT (2) PT2295049E (de)
RU (2) RU2493840C2 (de)
SG (1) SG165364A1 (de)
SI (2) SI1926483T1 (de)
TN (1) TNSN08103A1 (de)
TW (2) TWI376223B (de)
WO (1) WO2007028821A2 (de)
ZA (1) ZA200801694B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006009092A1 (ja) * 2004-07-16 2006-01-26 Kyorin Pharmaceutical Co., Ltd. 効果的な医薬の使用法及び副作用発現の防御に関する方法
CA2583846C (en) 2004-10-12 2013-10-01 Kyorin Pharmaceutical Co., Ltd. Process for producing 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl]-1,3-propanediol hydrochloride or hydrates thereof, and intermediates in the production thereof
WO2007043433A1 (ja) * 2005-10-07 2007-04-19 Kyorin Pharmaceutical Co., Ltd. ２－アミノ－１，３－プロパンジオール誘導体を有効成分とする肝臓疾患治療剤および肝臓疾患治療方法
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
KR20090041424A (ko) * 2006-08-08 2009-04-28 교린 세이야꾸 가부시키 가이샤 아미노알코올 유도체 및 그것들을 유효성분으로 하는 면역 억제제
KR101339976B1 (ko) * 2006-08-08 2013-12-10 교린 세이야꾸 가부시키 가이샤 아미노인산에스테르 유도체 및 그들을 유효성분으로 하는 ｓ1ｐ 수용체 조절제
US20100093745A1 (en) * 2007-02-13 2010-04-15 Kazuhiko Kuriyama Therapeutic agent or prophylactic agent for demyelinating disease comprising amino alcohol derivative as active ingredient
US8476305B2 (en) 2008-02-07 2013-07-02 Kyorin Pharmaceutical Co., Ltd. Therapeutic agent or prophylactic agent for inflammatory bowel disease comprising amino alcohol derivative as active ingredient
KR20110010638A (ko) * 2008-05-20 2011-02-01 교린 세이야꾸 가부시키 가이샤 관해 도입 유지제
CN102119028A (zh) * 2008-08-18 2011-07-06 诺瓦提斯公司 用于治疗脱髓鞘性周围神经病的氨基醇衍生物
JP2013530937A (ja) * 2010-05-06 2013-08-01 ノバルティス アーゲー 自己免疫疾患の処置剤
CN102917698A (zh) * 2010-05-06 2013-02-06 诺瓦提斯公司 二芳基硫醚衍生物的给药方案

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141421A (en) * 1991-12-17 1992-08-25 Carrier Corporation Nested coupling mechanism for scroll machines
DE4428835A1 (de) * 1994-08-01 1996-02-08 Schering Ag Neue 3-substituierte 3H-2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel
DK0990440T3 (da) * 1997-02-27 2009-02-23 Novartis Ag Farmaceutisk sammensætning indeholdende 2-amino-2[2-(4-octylphenyl)-ethyl]-propan-1,3-diol, en lecithin og et saccharid
CA2460640C (en) * 2001-09-27 2011-03-29 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivatives, salts thereof and immunosuppressive agents using the same
DK1431284T3 (da) * 2001-09-27 2008-02-18 Kyorin Seiyaku Kk Diarylsulfidderivat, additionssalt deraf samt immunundertrykkende middel
US7482491B2 (en) * 2002-09-19 2009-01-27 Kyorin Pharmaceutical Co., Ltd. Amino alcohol derivative, addition salt thereof, and immunosuppressant
TWI376363B (en) * 2002-09-24 2012-11-11 Novartis Ag Pharmaceutical combination for treating demyelinating disease
WO2004028511A1 (en) * 2002-09-28 2004-04-08 Mcneil-Ppc, Inc. Solid dosage form comprising ketoprofen
AU2004213297B2 (en) * 2003-02-18 2009-03-19 Kyorin Pharmaceutical Co., Ltd. Aminophosphonic acid derivatives, addition salts thereof and S1P receptor modulators
CN1767819B (zh) 2003-04-08 2010-07-28 诺瓦提斯公司 包含s1p受体激动剂和糖醇的固体药物组合物
WO2005014525A2 (en) * 2003-08-12 2005-02-17 Mitsubishi Pharma Corporation Bi-aryl compound having immunosuppressive activity
DE602004024213D1 (en) * 2003-08-28 2009-12-31 Novartis Ag Aminopropanolderivate
WO2006009092A1 (ja) * 2004-07-16 2006-01-26 Kyorin Pharmaceutical Co., Ltd. 効果的な医薬の使用法及び副作用発現の防御に関する方法
EP1819326B1 (de) * 2004-11-29 2014-07-02 Novartis AG Dosierungsplan eines s1p-rezeptoragonisten
GB0504544D0 (en) * 2005-03-04 2005-04-13 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
EP2295049A1 (de) 2011-03-16
KR20080046231A (ko) 2008-05-26
PT2295049E (pt) 2015-03-02
WO2007028821A2 (en) 2007-03-15
CN101257899B (zh) 2012-10-03
DK1926483T3 (da) 2011-03-14
EP1926483A2 (de) 2008-06-04
JO2655B1 (en) 2012-06-17
KR101476591B1 (ko) 2014-12-24
DE602006018629D1 (de) 2011-01-13
RU2493840C2 (ru) 2013-09-27
EP1926483B1 (de) 2010-12-01
PL2295049T3 (pl) 2015-04-30
AU2010224355A1 (en) 2010-10-14
RU2011111117A (ru) 2012-09-27
ES2357426T3 (es) 2011-04-26
WO2007028821A3 (en) 2007-05-03
SG165364A1 (en) 2010-10-28
EP2295049B1 (de) 2014-11-26
TW201034659A (en) 2010-10-01
JP2017019854A (ja) 2017-01-26
NZ566137A (en) 2011-05-27
ZA200801694B (en) 2009-09-30
HK1149906A1 (en) 2011-10-21
PT1926483E (pt) 2011-03-03
AU2006289100B2 (en) 2010-07-22
MA29787B1 (fr) 2008-09-01
JP2015025002A (ja) 2015-02-05
IL233328A0 (en) 2014-08-31
RU2424795C2 (ru) 2011-07-27
CA2820510A1 (en) 2007-03-15
IL189665A0 (en) 2008-06-05
AU2006289100A1 (en) 2007-03-15
JP2013010802A (ja) 2013-01-17
KR101476451B1 (ko) 2014-12-24
CA2620554A1 (en) 2007-03-15
ATE489948T1 (de) 2010-12-15
TWI376223B (en) 2012-11-11
MX2008003170A (es) 2008-03-18
CA2620554C (en) 2013-12-17
TW200803829A (en) 2008-01-16
IL189665A (en) 2014-07-31
ES2529724T3 (es) 2015-02-25
US20080200438A1 (en) 2008-08-21
KR20140019033A (ko) 2014-02-13
SI2295049T1 (sl) 2015-03-31
AU2010224355B2 (en) 2012-03-29
BRPI0615906A2 (pt) 2011-05-31
CY1111285T1 (el) 2015-08-05
KR20140117704A (ko) 2014-10-07
JP2009507810A (ja) 2009-02-26
SI1926483T1 (sl) 2011-04-29
PL1926483T3 (pl) 2011-05-31
JP5244598B2 (ja) 2013-07-24
NZ588372A (en) 2012-03-30
TNSN08103A1 (en) 2009-07-14
CN101257899A (zh) 2008-09-03
RU2008113187A (ru) 2009-10-20
TWI372620B (en) 2012-09-21
JP6077265B2 (ja) 2017-02-08
DK2295049T3 (en) 2015-02-23

Similar Documents

Publication Publication Date Title
NO20081727L (no) Behandling av autoimmune sykdommer
NO20054407L (no) Cannabinoid reseptor ligander og deres anvendelser
EA201070247A1 (ru) Ингибиторы протеасом
NO20072092L (no) Sulfonamidforbindelser
NO20081788L (no) Cyklopropylaminer som modulatorer av histamin-H3-reseptoren
NO20076401L (no) Diarylhydantoinforbindelser
DK2023918T3 (da) Cyclosporiner til behandlingen og forebyggelse af okulære lidelser
MX2009011211A (es) Indoles sustituidos en la posicion 7 inhibidores de mci-1.
ATE493418T1 (de) Dihydrofuropyrimidine als akt- proteinkinaseinhibitoren
UA85559C2 (en) Aminobenzophenone compounds
EA200702048A1 (ru) Фармакокинетически улучшенные соединения
NO20053042L (no) Anvendelse av spongosin (2-metoksyadenosin) for behandling av smerte, saerlig hyperalgesi.
ATE472529T1 (de) Prolinamidderivate als natriumkanalmodulatoren
EA200971077A1 (ru) Гетероциклические модуляторы киназы
CR10072A (es) Derivados de pirimidinil-aril-urea que son inhibidores de fgf
NO20076412L (no) Heterosykliske inhibitorer av mek og fremgangsmater for anvendelse derav
EA201000149A1 (ru) Производные 1-фенил-2-пиридинилалкиловых спиртов в качестве ингибиторов фосфодиэстераз
NO20080318L (no) Anvendelse av enkelt dose av CD-20-spesifikke bindingsmolekyler
NO20084712L (no) Nye farmasoytiske forbindelser
ATE532789T1 (de) Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren
NO20075706L (no) Pyrrolopyridinbaserte inhibitorer av dipeptidylpeptidase IV og metoder
EA200601074A1 (ru) Применение производных пептидов для лечения болей, связанных с заболеванием центральной нервной системы (центральной невропатической боли)
NO20075370L (no) Alfa-ketoamidforbindelser som cysteinproteaseinhibitorer
WO2006034391A3 (en) Indole inhibitors of 15-lipoxygenase
PL1912954T3 (pl) Nowe inhibitory proteaz cysteinowych i ich terapeutyczne zastosowania

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application